We are analyzing https://link.springer.com/article/10.1007/s002800050666.

Title:
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial | Cancer Chemotherapy and Pharmacology
Description:
Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

article, cancer, breast, atra, metastatic, patients, dose, privacy, cookies, content, chemotherapy, pharmacokinetics, phase, access, analysis, information, publish, search, alltrans, retinoic, acid, study, data, log, journal, research, pharmacology, clinical, impact, trial, sutton, warmuth, petros, initial, institution, disease, therapy, open, discover, springer, optional, personal, parties, policy, find, track, cite, linda, marc, william,

Topics {✒️}

phase ii trial month download article/chapter article cancer chemotherapy phase ii study trans retinoic acid metastatic breast cancer privacy choices/manage cookies anthracycline dose reduction related subjects full article pdf european economic area evaluate tumor cytoreduction conditions privacy policy treatment regimen consisted initial pharmacokinetics accepting optional cookies pharmacokinetic analysis revealed chemotherapy delays atra administered orally check access instant access journal finder publish systemic exposure article log article cite privacy policy personal data article sutton books a pharmacokinetics therapy optional cookies pharmacokinetic analysis information manage preferences medical oncology subscription content similar content initial dose institution subscribe data protection essential cookies usage analysis cookies skip meta-analysis adjuvant treatment journal publish pharmacology aims clinical pharmacology social media

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial
         description: Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA's clinical pharmacology, ultimately leading to improved efficacy.
         datePublished:
         dateModified:
         pageStart:335
         pageEnd:341
         sameAs:https://doi.org/10.1007/s002800050666
         keywords:
            Key words Retinoids
             All-trans retinoic acid Pharmacokinetics
             Breast neoplasms
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:40
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Linda M. Sutton
               affiliation:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                     address:
                        name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marc A. Warmuth
               affiliation:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                     address:
                        name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William P. Petros
               affiliation:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                     address:
                        name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric P. Winer
               affiliation:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                     address:
                        name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial
      description: Purpose: The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize the initial pharmacokinetics of this agent. Methods: The study was a single institution, phase II study. The treatment regimen consisted of ATRA administered orally at a dose of 50 mg/m2 three times a day for 14 consecutive days of a 21-day cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient withdrawal. Plasma samples were obtained following the first dose of ATRA for pharmacokinetic analysis. Results: A total of 17 patients with metastatic breast cancer were enrolled in the study, and 14 completed at least one cycle of therapy and were evaluable for response. One patient achieved a partial response in soft tissue of 4 months duration. Three patients had stable disease for 4, 2, and 2 months duration. The remainder had progressive disease. ATRA was reasonably well tolerated. Pharmacokinetic analysis revealed a high degree of interpatient variability in systemic exposure following the initial dose of ATRA. Conclusions: We conclude, that in the dose and schedule tested, ATRA does not have significant activity in patients with hormone-refractory, metastatic breast cancer. Future studies should focus on more intensive investigation of those individuals with very high or low ATRA initial systemic exposure in the hope of expanding our understanding of ATRA's clinical pharmacology, ultimately leading to improved efficacy.
      datePublished:
      dateModified:
      pageStart:335
      pageEnd:341
      sameAs:https://doi.org/10.1007/s002800050666
      keywords:
         Key words Retinoids
          All-trans retinoic acid Pharmacokinetics
          Breast neoplasms
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:40
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Linda M. Sutton
            affiliation:
                  name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                  address:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marc A. Warmuth
            affiliation:
                  name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                  address:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William P. Petros
            affiliation:
                  name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                  address:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric P. Winer
            affiliation:
                  name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
                  address:
                     name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:40
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
      address:
         name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
         type:PostalAddress
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
      address:
         name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
         type:PostalAddress
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
      address:
         name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
         type:PostalAddress
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
      address:
         name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Linda M. Sutton
      affiliation:
            name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
            address:
               name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
               type:PostalAddress
            type:Organization
      name:Marc A. Warmuth
      affiliation:
            name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
            address:
               name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
               type:PostalAddress
            type:Organization
      name:William P. Petros
      affiliation:
            name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
            address:
               name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
               type:PostalAddress
            type:Organization
      name:Eric P. Winer
      affiliation:
            name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221
            address:
               name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
      name:Division of Hematology and Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA Tel. (919) 684-3877; Fax (919) 684-4221, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(31)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.74s.

LINK . SPRINGER . COM {}